DDIT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Collectively, although there is limited evidence that CHOP or its variants improve the prognosis of patients with PTCL, there is also little evidence that a certain non-anthracycline combination can replace CHOP.